NCT04655807 2025-04-27
DUET
Janssen Research & Development, LLC
Phase 2 Withdrawn
Clinical Trials
12 trialsNCT01804166 2025-02-04
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Janssen Scientific Affairs, LLC
Phase 4 Completed
NCT02574637 2021-05-26
Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2 Terminated
NCT02499783 2019-01-04
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie
Phase 3 Completed
NCT01560377 2018-12-11
PILLAR II
Novadaq Technologies ULC, now a part of Stryker
Phase 1 Completed
NCT00552058 2018-08-09
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
UCB Pharma
Phase 3 Completed
NCT00333788 2018-08-07
Welcome2
UCB Pharma
Phase 3 Completed
NCT01369329 2016-12-07
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Janssen Research & Development, LLC
Phase 3 Completed
NCT00584740 2015-03-31
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
Novartis
Phase 2 Terminated
NCT00354367 2012-05-28
Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
UCB Pharma
Phase 3 Withdrawn
NCT00358683 2012-05-28
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
UCB Pharma
Phase 3 Withdrawn
NCT00297648 2011-08-31
MUSIC
UCB Pharma
Phase 3 Completed